- Checkpoint Therapeutics expects to report Cosibelimab’s top-line data in Q4 of this year. The company anticipates submitting a BLA and MMA next year with a potential launch in 2023.
- I have pushed CKPT aside several times, but I can no longer ignore its potential upside from Cosibelimab and its potential to disrupt a $25B+ checkpoint market.
- I review some of Cosibelimab’s data and match it up to some of the market’s leading PD-1 and PD-L1 agents.
- I reveal my investment strategy and long-term outlook.
For further details see:
Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data